Deutsche Biotech Innovativ AG Stock price

Equities

DBI

DE000A0Z25L1

Biotechnology & Medical Research

End-of-day quote BOERSE DUESSELDORF 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
1.04 EUR +2.97% Intraday chart for Deutsche Biotech Innovativ AG +4.00% -86.75%
Sales 2021 - Sales 2022 - Capitalization 25.39M 27.36M
Net income 2021 - 0 Net income 2022 - 0 EV / Sales 2021 -
Net cash position 2021 18.92K 20.4K Net cash position 2022 8.08K 8.7K EV / Sales 2022 -
P/E ratio 2021
-371 x
P/E ratio 2022
-107 x
Employees 1
Yield 2021 *
-
Yield 2022
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.97%
1 week+4.00%
Current month-74.00%
1 month-74.00%
3 months-86.75%
6 months-93.46%
Current year-86.75%
More quotes
1 week
1.00
Extreme 1
1.04
1 month
0.95
Extreme 0.95
1.10
Current year
0.95
Extreme 0.95
6.00
1 year
0.95
Extreme 0.95
17.10
3 years
0.95
Extreme 0.95
102.00
5 years
0.95
Extreme 0.95
127.00
10 years
0.95
Extreme 0.95
127.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 76 08-12-31
Chief Operating Officer 65 19-10-06
Members of the board TitleAgeSince
Chief Executive Officer 76 08-12-31
Chief Operating Officer 65 19-10-06
Chairman 64 11-02-14
More insiders
Date Price Change Volume
24-03-28 1.04 +2.97% 16
24-03-27 1.01 0.00% 214
24-03-26 1.01 +1.00% 214
24-03-25 1 0.00% 214
24-03-22 1 0.00% 396

End-of-day quote BOERSE DUESSELDORF, March 27, 2024

More quotes
Deutsche Biotech Innovativ AG, formerly Venetus Beteiligungen AG, is a Germany-based biotechnology company. The Company focuses on the identification of relevant biomarkers in the blood of affected patients, and also develops targeted therapies to prevent septic shock and inhibit tumor growth, as well as a small molecule drug for breast cancer prevention. . Its product portfolio comprises various indicators, among others, for sepsis therapy (Adrecizumab), for breast cancer prevention (DB1RA) and for cancer therapy (AB2302). Its research and development activities are entirely conducted by project companies, in which the Company holds interest. The Company's subsidiaries include AngioBiomed GmbH, AdrenoMed AG, Oncoprevent GmbH and MyLife Diagnostics GmbH.
More about the company
  1. Stock
  2. Equities
  3. Stock Deutsche Biotech Innovativ AG - BOERSE DUESSELDORF